Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatologists Struggle with Drug Shortages

Thomas R. Collins  |  Issue: October 2011  |  October 7, 2011

Dr. Dao says, “some patients have been resourceful.”

Some, like Greenway, have been dogged with insurance coverage, with mixed success. Others have managed to buy their drug from hospital pharmacies and others have warily bought their medication online. If their attempts fail, they check with the doctor about alternatives.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Greenway seems to have been fortunate. She says she now has the name of a helpful supervisor with the insurance company she hopes will allow her to circumvent much of the frustration next time. “It’s not my fault that they’re not making the generic,” she says. “But, unfortunately, it’s my problem.”

Rheumatology Feeling the Lack

Dr. Cush emphasizes that drug shortages in rheumatology, while a serious problem, have not risen to a catastrophic level. He says that none of his patients has suffered permanent harm or damage due to a drug shortage, as has been seen with cancer patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“While there are certain patients who’ve been inconvenienced by this, I would not say this has been a show-stopper for rheumatology,” he says. “We have enough alternatives that short supply has not shut down patient care.”

Dr. Fudman says that, for many patients, there is only one optimal drug.

“There’s not such a wide variety of drugs in rheumatology that it’s easy to switch off of various things,” he says. “If somebody’s on methotrexate, they’re on methotrexate. If they’re on leflunomide, they’re on leflunomide. These are drugs that take a long time to build up their efficacy. It’s not something you can switch back and forth.”

The FDA says it confirmed 178 cases of drug shortages in 2010—a record number. That was up from 55 shortages five years ago.1

According to the University of Utah Drug Information Service, there were 120 shortages reported in the U.S. in 2001—but that number has risen to 211 in 2010.

Through September of this year, 200 shortages were reported.2

Senate Bill Would Require Advance Notice of Potential Shortage

If rheumatologists and pharmacists were to get early warning that a drug might soon be in short supply, they may be able to better prepare their patients and help them adapt, perhaps pursuing other medications sooner, if possible.

Advance notice, though, is often more of a wish than a reality.

But a bill (S. 296) proposed in the U.S. Senate by Sens. Amy Klobuchar (D-Minn.) and Bob Casey (D-Pa.) would require that drug manufacturers notify the U.S. Food and Drug Administration of factors that might lead to a drug shortage.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Practice Support Tagged with:Drug SafetyDrugsFDArheumatologyshortage

Related Articles

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    Colcrys Approval Triggers Questions

    May 1, 2010

    Some rheumatologists question the depth of research and the approval’s implications for patient access

    Drug Shortages in U.S. Emergency Departments on the Rise

    January 17, 2016

    (Reuters Health)—U.S. emergency rooms are increasingly running short on medications, including many that are needed for life-threatening conditions, a recent study documents. Since 2008, the number of shortages has risen by more than 400%, researchers found. Half of all emergency room shortages were for life-saving drugs, and for one in 10 there were no available…

    Drug Updates

    May 16, 2011

    Information on New Approvals and Medication Safety

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences